# 7wire Ventures

> 7wire Ventures is a VC fund in Chicago backing Health Care and Medical. See 86 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chicago, United States
- Total investments: 86
- Last investment: Jul 2026
- Lead investor: 38%
- Fund size: $150M
- Last fund: May 2021
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/7wire-ventures
- X (Twitter): http://twitter.com/7wireventures
- Website: http://7wireventures.com/
- Facebook: http://www.facebook.com/7wireVentures

7wire Ventures is a VC fund in Chicago focused on Health Care and Medical. 7wire ventures focuses on investing in early and growth-stage companies focused on healthcare IT, digital healtcare and mobile health.

## Contacts

5 contacts available for 7wire Ventures. Shizune tracks 7 team members at 7wire Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/7wire-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.9M–$25M |
| Series B | $7.5M–$45M |
| Series C | $20M–$105M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 35 | 41% |
| Medical | 14 | 16% |
| Wellness | 14 | 16% |
| Fitness | 5 | 6% |
| Medical Device | 5 | 6% |

50 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 25 | 29% |
| Series B | 19 | 22% |
| Series C | 10 | 12% |
| Seed | 9 | 10% |
| Series D | 4 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 45% |
| Canada | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lee Shapiro | Co-Founder & Managing Partner | 26 | https://shizune.co/investors/profile/lee-shapiro |
| Robert Garber | Managing Partner | 13 | https://shizune.co/investors/profile/robert-garber |
| Alyssa Jaffee | Partner | 11 | https://shizune.co/investors/profile/alyssa-jaffee |
| David Schonthal | Operating Partner | 1 | https://shizune.co/investors/profile/david-schonthal |
| Glen Tullman | Co-Founder & Managing Partner | 17 | https://shizune.co/investors/profile/glen-tullman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Karoo Health | Karoo Health is a leader in tech-enabled value-based cardiovascular care solutions and aims to bring innovative, end-to-end, cardiovascular solutions to patients via partnerships with health plans and self-insured employers. As a patient-first organization, Karoo Health’s mission is to help patients lead their best lives by providing a new paradigmof better cardiology care, at lower cost, than the current system and preventing the progression of cardiovascular disease. | $16.2M | Series A | Jul 20, 2026 |  |
| When Insurance | When Insurance is a technology platform that helps individuals and employers navigate health insurance options during transitions such as job loss or retirement. It connects users with a marketplace of health plans from third-party providers and offers tools to compare and apply for coverage alternatives to COBRA, including personalized guidanceand reimbursement options for premiums. The platform integrates with HR systems to support workforce offboarding, provides concierge support from licensed advisors, and assists with Medicare navigation and healthcare reimbursement benefits. When Insurance operates as an intermediary facilitating access to health insurance choices rather than selling insurance directly. | $10.2M | Series A | Jan 30, 2026 |  |
| WellTheory | WellTheory provides a virtual care platform focused on autoimmune and inflammatory health. It delivers personalized nutrition, lifestyle, and root-cause assessments, then matches each member with a multidisciplinary Care Team including dietitians, health coaches, and support coordinators. The company supports users through live coaching sessions,unlimited messaging, educational content, community connection, and advanced testing as needed. For employer and payer customers, it offers an enterprise solution that integrates with existing benefit systems, handles implementation, communications, and reporting, and aims to reduce autoimmune-related medical spend. | $14M | Series A | Oct 14, 2025 |  |
| Homethrive | Homethrive provides care management and personal assistance services to help older adults live at home with dignity and purpose while reducing the stress, strain, work, and worry for their family members. | $20M | Series B | Nov 14, 2024 |  |
| Hippocratic AI | Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $17M | Series A | Sep 19, 2024 |  |
| PayZen | PayZen is a healthcare fintech startup that aims to tackle the growing patient payment responsibility problem. The mission-driven company together with its superior technology and a new approach enables patients to pay their out-of-pocket medical bills over time with convenience and transparency. While Medical Providers should be able to focus onproviding healthcare services rather than financial services. The company achieves better financial outcomes for both patients and providers through Smart Medical Payment Plans And Non-Recourse Patient Financing.Ariel Rosenthal, Itzik Cohen, and Tobias Mezger co-founded the company in San Francisco, California in 2019. | $32M | Series B | Aug 13, 2024 |  |
| PayZen | PayZen is a healthcare fintech startup that aims to tackle the growing patient payment responsibility problem. The mission-driven company together with its superior technology and a new approach enables patients to pay their out-of-pocket medical bills over time with convenience and transparency. While Medical Providers should be able to focus onproviding healthcare services rather than financial services. The company achieves better financial outcomes for both patients and providers through Smart Medical Payment Plans And Non-Recourse Patient Financing.Ariel Rosenthal, Itzik Cohen, and Tobias Mezger co-founded the company in San Francisco, California in 2019. | $32M | Series B | Aug 13, 2024 |  |
| Truvian Sciences | Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M |  | Jul 17, 2024 |  |
| Truvian Sciences | Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M | Series D | Jul 17, 2024 |  |
| Transcarent | Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care. | $126M | Series D | May 02, 2024 |  |

10 of 86 investments shown.

## Co-investors
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 27 deals together
- [Human Capital](https://shizune.co/investors/profile/human-capital-da7c) — VC Fund, 13 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 11 deals together
- [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund) — VC Fund, 11 deals together
- [Threshold](https://shizune.co/investors/profile/threshold) — VC Fund, 8 deals together
- [Cigna Ventures](https://shizune.co/investors/profile/cigna-ventures) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Wellness Investors](https://shizune.co/investors/wellness-investors)
- [Wellness VC Funds](https://shizune.co/investors/wellness-vc-funds)
- [Wellness Investors in United States](https://shizune.co/investors/wellness-investors-united-states)
- [Fitness VC Funds](https://shizune.co/investors/fitness-vc-funds)
- [Fitness Investors in United States](https://shizune.co/investors/fitness-investors-united-states)
- [Fitness VC Funds in United States](https://shizune.co/investors/fitness-vc-funds-united-states)

## FAQ

### What does 7wire Ventures invest in?

7wire Ventures invests primarily in Health Care, Medical and Wellness startups, most often at Series A and Series B stage. Most of the 86 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is 7wire Ventures's check size?

7wire Ventures typically joins rounds of $4.9M–$25M at Series A, $7.5M–$45M at Series B and $20M–$105M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 7wire Ventures participates in.

### How do I contact 7wire Ventures?

Public channels for 7wire Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 7wire Ventures?

The team at 7wire Ventures includes Lee Shapiro (Co-Founder & Managing Partner), Robert Garber (Managing Partner) and Alyssa Jaffee (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co